While various therapies exist for treating different breast cancer subtypes, such as established hormonal therapy for HER-2 positive cases, the effectiveness of HER2-based therapies is anticipated to be limited in basal-like breast cancer (BLBC) [12–14]. Here, ERBB2 is linked to breast carcinoma.